Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R
In Vitro Fertilization and Infertility Unit., Department of Obstetrics & Gynecology, Assaf Harofeh Medical Center, Zerifin, Israel.
J Assist Reprod Genet. 2001 Apr;18(4):197-204. doi: 10.1023/a:1009476411762.
To assess the efficacy of a protocol involving the discontinuation of the GnRH analogue at the mid-phase of ovarian stimulation for IVF in patients with a previous poor response.
Prospective case-control evaluation compared with same patient's previous performance. Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles. The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group). Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group). All clinical and laboratory aspects of treatment were done in a similar fashion in both cycles, each patient acting as her own control.
Results were analyzed by paired t test. The change in each parameter in the N-stop cycle was expressed as the percent change as compared with the standard protocol cycle for each patient. Peak estradiol (E2) and number of aspirated oocytes were increased in the N-stop cycle (+16.9% and +28%, respectively), but insignificantly so. The percent of cleaving embryos was significantly increased by 27.9% (p = 0.03) in the N-stop cycle, as embryo morphology was improved by 22% (p = 0.02). The efficacy of gonadotropin treatment was enhanced in the N-stop cycle, as expressed by a 32.5% increase in oocytes retrieved per hMG ampoule administered (p = 0.04). Three cycles of 36 were cancelled during the N-stop cycle, whereas only one was cancelled in the standard protocol cycle. Of the 36 patients, 7 conceived in the N-stop protocol and 5 are ongoing pregnancies.
Discontinuation of GnRH-a during ovarian stimulation for IVF has a beneficial, but not statistically significant, effect on both E2 and oocyte production. Embryo cleavage rates and morphology were significantly improved, this may be due to improved oocyte quality, which may have been responsible for achieving pregnancies. The efficacy of gonadotropin treatment was enhanced when GnRH-a was discontinued. These results hint that GnRH-a may have a direct negative effect on folliculogenesis and oocytes, which is apparent especially in poor responder patients.
评估在既往反应不良的患者体外受精(IVF)卵巢刺激中期停用促性腺激素释放激素(GnRH)类似物方案的疗效。
前瞻性病例对照评估,并与同一患者既往的表现进行比较。36名参加IVF项目的患者连续接受两个周期的治疗。第一个周期采用标准化方案,在黄体中期给予那法瑞林(N)600微克/天,并在整个刺激阶段持续使用人绝经期促性腺激素(hMG),直至经阴道超声检查发现直径达20毫米的卵泡(标准组)。在标准周期中反应不良的患者,在随后的周期中最初以类似方式接受N和hMG治疗,然后在hMG刺激5天后停用N(N停药组)。两个周期的所有临床和实验室治疗环节均以类似方式进行,每位患者作为自身对照。
采用配对t检验分析结果。N停药周期中每个参数的变化表示为与每位患者标准方案周期相比的变化百分比。N停药周期中雌二醇峰值(E2)和吸出的卵母细胞数量增加(分别增加16.9%和28%),但增加不显著。N停药周期中分裂胚的百分比显著增加27.9%(p = 0.03),因为胚胎形态改善了22%(p = 0.02)。N停药周期中促性腺激素治疗的疗效增强,表现为每注射一支hMG回收的卵母细胞增加32.5%(p = 0.04)。N停药周期中有3个周期(共36个周期)取消,而标准方案周期中仅1个周期取消。36名患者中,7名在N停药方案中受孕,5名正在妊娠。
IVF卵巢刺激期间停用GnRH-a对E2和卵母细胞产生有有益但无统计学意义的影响。胚胎分裂率和形态显著改善,这可能是由于卵母细胞质量提高,这可能是实现妊娠的原因。停用GnRH-a时促性腺激素治疗的疗效增强。这些结果提示GnRH-a可能对卵泡发生和卵母细胞有直接负面影响,这在反应不良患者中尤为明显。